Gene Expression Profiling of TNBC and OVCA in response to Azacitidine and Talazoparib (RNA-Seq)

ABSTRACT: Triple negative breast cancer and ovarian cancer cells were treated with Azacitidine, Talazoparib, or combination for a period of 10 days to assess global transcriptional response. The focus of these transcriptional studies were on the assessment of DNA repair and immune pathway alteration.

ORGANISM(S): Homo sapiens

PROVIDER: GSE151317 | GEO | 2020/05/28

REPOSITORIES: GEO